^
Association details:
| Biomarker: | CRBN elevation + SPARC-L |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + azacitidine (DNMT inhibitor) + dexamethasone (GCR agonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Extracellular RNA: An emerging biomarker for therapeutic monitoring in multiple myeloma
Published date:
08/28/2021
Excerpt:
Evaluation of LEN-related exRNA transcripts utilising ddPCR in the ROAR trial indicated that high Cereblon (CRBN) levels coupled with low levels of SPARC at baseline were associated with shorter OS (p<0.001)....We investigated this concept in the “validation cohort” (Kappamab trial) and observed results consistent to that of the “test cohort”, which showed that lower levels of SPARC and higher levels of IKZF3 were indicators of poor prognosis (p<0.05)
